P. Pancheri, R. Delle Chiaie - Vol. 7, Marzo 2001, num.1
Testo Immagini Bibliografia Summary Riassunto Indice
Terapia sintomatica e terapia patogenetica dell’ansia
generalizzata
Symptomatic and pathogenetic therapy of generalized anxiety
1 Kessler RC, Nelson CB, McGonagic KA. Comorbidity of DSM III-R major
depressive disorder in the general population: results from the US National
Comorbidity Survey. Br J Ps 1996;168(Suppl 30):17-30.
2 American Psychiatric Association. Diagnostic and Statistical Manual of
Mental Disorders, 4th Edition (DSM-IV) Washington, D.C.: American Psychiatric
Association 1994.
3 American Psychiatric Association. Diagnostic and Statistical Manual of
Mental Disorders, 2nd Edition (DSM-II).Washington, D.C.: American Psychiatric
Association 1968.
4 American Psychiatric Association. Diagnostic and Statistical Manual of
Mental Disorders, 3rd Edition (DSM-III). Washington, D.C.: American Psychiatric
Association 1980.
5 American Psychiatric Association. Diagnostic and Statistical Manual of
Mental Disorders, 3rd Edition-Revised (DSM-III-R). Washington, D.C.: American
Psychiatric Association 1987.
6 Roth M, Mountojoy C. Classification and diagnosis of anxiety and depressive
disorders and some implications for clinical practice and enquiry. Hum
Psychopharm 1999;14:S40-S-71.
7 Yonkers KA, Dyck IR, Warshaw M, Keller M. Factors predicting the clinical
course of generalized anxiety disorder. Br J Ps 2000;176:S44-S49.
8 Klein DF. Delineation of two drug responsive anxiety syndromes. Psychopharmacologia
1964;5:397-408.
9 Kahn RJ, McNair DM, Lipman RS, Covi L, Rickels K, Downing R, et al.
Imipramine and chlordiazepoxide in depressive and anxiety disorders. II.
Efficacy in anxious outpatients. Arch Gen Psychiatry 1986;43:79-85.
10 Lipman RS, Covi L, Rickels K, McNair DM, Downing R, Kahn RJ, et al. Imipramine
and chlordiazepoxide in depressive and anxiety disorders. I. Efficacy in depressed
outpatients. Arch Gen Psychiatry 1986;43:68-77.
11 Lapierre YD. The comparative anxiolytic effects of placebo, imipramine
and chlorimipramine using psychiatric and psychophysiological measurements.
Int J Clin Pharmacol 1974;9:16-22.
12 Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the
treatment of generalized anxiety disorder. A placebo-controlled comparison
of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993;50:884-95.
13 Feighner JP, Cohn JB. Analysis of individual symptoms in generalized
anxiety - a pooled, multistudy, double-blind evaluation of buspirone.
Neuropsychobiology 1989;21:124-30.
14 Strand M, Hetta J, Rosen A, Sorensen S, Malmstrom R, Fabian C, et al. A
double-blind, controlled trial in primary care patients with generalized anxiety:
a comparison between buspirone and oxazepam. J Clin Psychiatry 1990;51(Suppl
9):40-5.
15 Enkelmann R. Alprazolam versus buspirone in the treatment of outpatients
with generalized anxiety disorder. Psychopharmacology (Berl) 1991;105:428-32.
16 Sheehan DV, Raj AB, Sheehan KH, Soto S. The relative efficacy of buspirone,
imipramine and placebo in panic disorder: a preliminary report. Pharmacol
Biochem Behav 1988;29:815-7.
17 Pohl R, Balon R, Yeragani VK, Gershon S. Serotonergic anxiolytics in
the treatment of panic disorder: a controlled study with buspirone. Psychopathology
1989;22(Suppl 1):60-7.
18 Cottraux J, Note ID, Cungi C, Legeron P, Heim F, Chneiweiss L, et al. A
controlled study of cognitive behaviour therapy with buspirone or placebo
in panic disorder with agoraphobia. Br J Psychiatry 1995;167:635-41.
19 Graeff FG, Guimaraes FS, De Andrade TG, Deakin JF. Role of 5-HT in stress,
anxiety, and depression. Pharmacol Biochem Behav 1996;54:129-41.
20 Deakin JFW Three distinct roles of of 5-HT in anxiety, panic and depression.
In: Montgomery SA, Corn TH, eds. Psychopharmacology of Depression.
Oxford: Oxford University Press 1994: 87-101.
21 Judd LL, Kessler RC, Paulus MC, Zeller PV, Wittchen HU, Kunovac JL. Comorbidity
as a fundamental feature of generalized anxiety disorder: results from the
National Comorbidity Study. Acta Psychiatr Scand 1998;98(Suppl 393):6-11.
22 Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSMIII-R Generalized Anxiety
Disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:355-64.
23 Rogers PM, Warshaw M, Goisman RM, Goldenberg I, Rodriguez-Villa F, Mallya
G. Comparing primary and secondary generalized anxiety disorder in a long
term naturalistic study of anxiety disorders. Depress Anxiety 1999;10:1-7.
24 Goldberg DP, Rickels K, Downing R, Hesbacer P. A comparison of two psychiatric
screening tests. Br J Psychiatry 1976;129:61-7.
25 Huppert FA, Walters DE, Day NE, Elliott BJ. The factor structure of
the General Helath Questionnaire (GHQ-30). A reliability study on 6317 community
residents. Br J Psychiatry 1989;155:178-85.
26 Pasquini M, Biondi M, Picardi A, Gaetano P, Pancheri P. MMPI-2 e dimensioni
psicopatologiche dei disturbi depressivi: uno studio di analisi fattoriale
in una popolazione ambulatoriale. Riv Psichiatria 1999;34:200-7.
27 Kahn RS, Westenberg HG, Moore C. Increased serotonin function and panic
disorder. In: Asnis GM, van Praag HM, eds. Panic Disorder. Chichester:
John Wiley & Sons, Baffins Lane 1995.
28 Engel JA, Hjorth S, Svensson K, Carlsson A. Anticonflict effect of the
putative serotonin receptor agonist 8-OH-DPAT. Eur J Pharmacol 1984;105:365-8.
29 Geller I, Blum K. The effects of 5-HTP on p-CPA attenuation of conflict
behavior. Eur J Pharmacol 1970;9:319-24.
30 Shepard RA, Buxton DA, Broadhurst PL. Drug interactions do not support
reduction in serotonin turnover as the mechanism of action of the benzodiazepines.
Neuropharmacology 1982;21:1027-32.
31 Tye NC, Iversen SD, Green AR. The Effects of benzodiazepines and serotonergic
manipulations on punished responding. Neuropharmacology 1979;18:689-95.
32 Briley M, Chopin P, Moret C. Effect of serotonergic lesions on "anxious"
behavior measured in the elevated plus-maze test in the rat. Psychopharmacology
1990;101:187-9.
33 File SE, Hyde JR, Macleod NK. 5,7-Dihydroxytryptamine lesions of dorsal
and medial raphe nuclei and performance in the social interaction test of
anxiety and in an home cage aggression test. J Affect Disord 1979;1:115-22.
34 Clarke A, File SE. Selective neurotoxin lesions of the lateral septum:
changes in social and aggressive behaviors. Pharmacol Biochem Behav 1982;17:623-8.
35 Graeff FG, Schoenfeld RI. Tryptaminergic mechanisms in punished and
non-punished behavior. J Pharmacol Exp Ther 1970;173:277-83.
36 Jenk F, Broekkampp CL, van Delft AM. Opposite control mediated by central
5HT-1a and non 5HT-1a receptors on periacqueductal gray aversion. Eur
J Pharmacol 1989;161:219-21.
37 Erickssen E, Westberg P, Alling G, Thuresson K, Modigh K. Cerebrospinal
fluid levels of monoamine metabolites in panic disorder. Psychiatry Res
1991;36:243-248.
38 Charney DS, Woods SW, Goodman WK, Heninger GR. Serotonin function in
anxiety: II. Effects of the serotonin agonist mCPP in panic disorder patients
and healthy subjects. Psychopharmacology 1987;92:14-24.
39 Targum SD, Marshall LE. Fenfluramine provocation of anxiety in patients
with panic disorder. Psychiatry Res 1989;36:75-84.
40 Charney DS, Heninger GR. Serotonergic function in panic disorder.
Arch Gen Psychiatry 1986;43:1059-65.
41 Pallanti S, Quercioli L, Rossi A, Pazzagli A. The emergence of social
phobia during clozapine treatment and its response to fluoxetine agmentation.
J Clin Psychiatry 1999;60:819-23.
42 Hollander E, Decaria CM, Trungold S. 5HT function and neurology of social
phobia [Abstract N° NR350:132]. In: New Research Program and Abstracts
of the 144-th Annual Meeting of the American Psychiatric Association.
New Orleans: May 14 1991.
43 Grove G, Coplan. The neuroanatomy of serotonin dysregulation in obsessive
compulsive disorder. CNS Spectrums 1996;1:16-22.
44 Arora RC, Fichtner CG, O’Connor F, Crayton JV. Paroxetine binding in
the blood platelets of post-traumatic stress disorder patients. Life Sci
1993;53:919-28.
45 Fichtner CG, Arora RC, O’Connor F, Crayton JV. Platelet paroxetine binding
and fluoxetine pharmacotherapy in post-traumatic stress disorder: preliminary
observations on a possible predictor of clinical treatment response. Life
Sci 1994;54:39-44.
46 Southwick SM, Yehuda R, Morgan CA. Clinical studies of neurotransmitter
alteration in post-traumatic stress disorder. In: MJ Friedman, DS Charney,
AY Deutsch, eds. Neurobiological and clinical consequences of stress: From
National Adaptation to Post-Traumatic Stress Disorder. New York: Lippicroft-Raven
1995.
47 Shader RI, Greenblatt DJ. The parmacotherapy of acute anxiety. In:
BloomFE, Kupfer DJ, eds. Psychopharmacology. The fourth generation of progress.
New York: Raven Press 1995.
48 Garvey MJ, Noyes RJ, Woodman C, Laukes C. Relationship of generalized
anxiety symptoms to urinary 5-hydroxyindolacetic acid and vanillylmandelic
acid. Psychiatry Res 1995;29:1-5.
49 Katz RJ, Landau PS, Lott M, Bystritsky A, Diamond B, Hoen-Saric R, et al.
Serotonergic mediation of anxiety-therapeutic effects of serazepine in
generalized anxiety disorder. Biol Psychiatry 1993;34:41-4.
50 Shweizer E, Rickles K. Issues in the long term treatment of anxiety
disorders. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology. The Fourth
Genration of Progress. New York: Raven Press 1995.
51 Albanesi G. Terapia dell’ansia. Milano: Masson 1995.
52 Gammans RE, Stringfellow JC, Hvizdos AJ. Use of buspirone in patients
with generalized anxiety disorder coexisting with depressive symptoms. A meta-analysis
of eight randomized controlled studies. Neuropsychobiology 1992;25:193-201.
53 Ross CA, Matas M. A clinical trial of buspirone and diazepam in the
treatment of generalized anxiety disorder. Can J Psychiatry 1987;32:351-5.
54 Ansseau M, Papart P, Gérard MA. Controlled comparison of buspirone
and oxazepam in generalized anxiety. Neuropsychobiology 1990;24:74-8.
55 Delle Chiaie R, Pancheri P, Casacchia M, Stratta P, Kotzalidis GD, Zibellini
M. Assessment of the efficacy of buspirone in patients affected by generalized
anxiety disorder, shifting to buspirone from prior treatment with lorazepam:
a placebo controlled double-blind study. J Clin Psychopharmacol 1995;15:12-19.
56 Enkelman R. Alprazolam vs buspirone in the treatment of outatients with
generalized anxiety disorder. Psychopharmacology (Berl) 1991;105:428-32.
57 Bohm C, Placchi M, Stallone F. A double blind comparison of buspirone,
clobazam and placebo in patients with anxiety treated in general practice
setting. J Clin Psychoparmacol 1990;10(Suppl 3):38-42.
58 Feighner JP. Buspirone in the long term treatment of generalized anxiety
disorder. J Clin Psychiatry 1987;48 (Suppl 12):3-6.
59 Petracca A, Nisita C, McNair D, Melis G, Guerani G, Cassano GB. Treatment
of generalized anxiety disorder. Preliminary experience with buspirone.
J Clin Psychiatry 1990;51(Suppl 9):31-9.
60 Khan RJ, McNair DM, Lipman RS. Imipramine and chloridazepoxide in depressive
and anxiety disorders. II Efficacy in anxious outpatients. Arch Gentile
Psychiatry 1986;43:79-85.
61 Hoehn-Sarie R, McLeod DR, Zimmerli WD. Differential effects of alprazolam
and imipramine in generalized anxiety disorder: somatic versus psychic symptoms.
J Clinic Psychiatry 1988;49:293-301.
62 Rickles K, Downing R, Schwizer E, Hassman H. Antidepressants for the
treatment of Generalized Anxiety Disorders. A placebo controlled comparison
of imipramine, trazodone and diazepa. Arch Gen Psychiatry 1993;50:884-95.
63 McLeod DR, Hoehn-Saric R, Zimmerli W, De Souza EB, Oliver LK. Treatment
effects of alprazolam and imipramine: physiological vs. subjective changes
in patients with genralized anxiety disorder. Biol Psychiatry 1990;28:849-61.
64 Delini Stula A, Cameron A, Angst J Comparative efficacy of antidepressants
on anxiety features in depression: a meta-analysis of double blind studies
of imipramine and moclobemide against placebo. Int J Pschiatry in Clinical
Practice 2000;4:111-7.
65 Pancheri P, Romiti R. Il ruolo di Venlafaxina a rilascio prolungato
nel trattamento dell’ansia generalizzata. Gior Itali Psicopat 2000;6:410-28.
66 Beique JC, de Montigny C, Blier P, Debonnel G. Blockade of 5-hydroxytryptamine
and noradrenaline uptake by venlafaxine: a comparative study with paroxetine
and desipramine. Br J Pharmacol 1998;125:526-32.
67 Davidson JR, DuPont RL, Hedges D, Haskins JT. Efficacy, safety, and
tolerability of venlafaxine extended release and buspirone in outpatients
with generalized anxiety disorder. J Clin Psychiatry 1999;60:528-35.
68 Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E.
Efficacy of venlafaxine extended-release capsules in nondepressed outpatients
with generalized anxiety disorder: A 6-month randomized controlled trial.
JAMA 2000;283:3082-8.
69 Rickels K, Pollack MH, Sheehan DV, Haskins JT. Efficacy of extended-release
venlafaxine in nondepressed outpatients with generalized anxiety disorder.
Am J Psychiatry 2000;157:968-74.
70 Hacket D, Parks V, Salinas E. A 6 month evaluation of 3 dose levels
of venlafaxine extended release in non-depressed outpatients with generalized
anxiety disorder. Anxiety Disorder Association of America, 19° Annual
Conference, 25-28 march 1999, San Diego, California.
71 Conti L, Pinder RM. A controlled comparative trial of mianserin and
diazepam in the treatment of anxiety states in psychiatric out-patients.
J Int Med Res 1979;7:285-9.
72 Bjaertnaes A, Block JM, Hafstad PE. A multicenter placebo-controlled
trial comparing the efficacy of mianserin and chlordiazepoxide in general
clinical practice with primary anxiety. Acta Psychiatr Scand 1982;66:199-207.
73 Westenberg HG, den Boer JA, Kahn RS. Psychopharmacology of anxiety disorders:
on the role of serotonin in the treatment of anxiety states and phobic disorders.
Psychopharmacol Bull 1987;23:145-9.
74 Birmaher B, Watrman GS, Ran D. Fluoxetine for childhood anxiet disorders.
J Am Acd Child Adolesc Psychiatry 1994;33:993-9.
75 Den Boer JA, Westenberg HG, Kamerbeek WD, Verheven WM, Kahn RS. Effecs
of serotonin uptake inhibitors in anxiety disorders: a double blind comparison
of clomipramine and fluvoxamine. Int Clin Psychopharmacol 1987;2:21-32.
76 Sonawalla SB, Spillmann MK, Kolsky AR, Alpert JE, Nierenberg AA, Rosenbaum
JF, et al. Efficacy of fluvoxamine in the treatment of major depression
with comorbid anxiety disorders. J Clin Psychiatry 1999;60:580-3.
77 Carrasco JL, Diaz Marsa L, Saiz Ruz J. Sertraline in the treatment of
mixed anxiety and depression disorder. J Affect Disord 2000;59:67-9.
78 Allgulander C, Cloninger CR, Przybeck TR, Brandt L. Changes on the Temperament
and Charcter Inventory after paroxetine treatment in volunteers with generalized
anxiety disorder. Psychopaharmacol Bull 1998;34:165-6.
79 Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L. Paroxetine efficacy
in the treatment of generalized anxiety disorder. Acta Psychiatr Scand
1997;95:444-50.
80 Data on file. Smithkline-Beecham 2000.
81 Breier A, Charney DS, Heninger GR. Agoraphobia with panic attacks: Development,
diagnostic stability and course of illness. Arch Gen Psychiatry 1986;43:102-1036.